Skip to content
Open access

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Aug 2026 · Transplantation and Cellular Therapy · 0 citations · 33 references
Medicine

TL;DR

Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is effective for treating relapsed or refractory B-cell lymphoma; however, its outcomes remain heterogeneous. We conducted a nationwide retrospective registry study in Japan to assess whether pretreatment body mass index (BMI) influences outcomes after CD19-directed CAR T-cell therapy. Among 944 patients with relapsed or refractory B-cell lymphoma treated between 2019 and 2024, BMI was categorized as Low (<18.5 kg/m²; n = 166), Normal (18.5 to 24.9 kg/m²; n = 619), or High (≥25 kg/m²; n = 159). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse or progression (CIR), non-relapse mortality (NRM), and CAR T-cell-related toxicities. Six-month OS rates in the low, normal, and high BMI groups were 73.2%, 83.7%, and 89.3%, respectively (P < .01), and corresponding PFS was 62.3%, 75.6%, and 77.7% (P < .01). CIR was more frequent in the Low-BMI group, whereas NRM did not differ significantly across groups. In the overall cohort, Low-BMI was associated with shortened OS and PFS and higher CIR in multivariable analyses. In a complete-case sensitivity analysis restricted to patients with available disease status data at the time of infusion, these associations were attenuated after adjusting for disease status. Severe CAR T-cell-related toxicities were comparable across BMI groups. Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.

Read PDF

Similar papers

Meta-analysis Open access Sep 2026

Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis

Higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICI therapy, with the most consistent favorable association observed for obesity, warranting cautious interpretation.

Si-Yu Sun, Jun-Hao Zhang, Yan Li et al. · 0 citations
Open access Sep 2026

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Exploratory multi-omic profiling linked durable response to higher CD22 antigen density on blasts; pre-infusion CD4 CAR-T cells expressing IL7Rα, LEF1, BACH2, and TCF7 but lower FOXP3; post-infusion NK-like effector CAR-T expansion; and central-memory CAR-T pool maintenance.

M. Seng, Ze-Xi Guo, Kai Soon Ng et al. · 1 citation
Open access Sep 2026

Efficacy and Safety of CAR‐T Cell Therapy in Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia With Central Nervous System Involvement

In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement, and consolidative allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients.

Yang-Hong Yu, Hui Xu, Lei Xue et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.